How Much NMN Per Day? The Doses Used in 20 Human Studies

White capsules on a tray next to a small lab scale and a notebook

How much NMN did people actually take in research? We went through PubMed and wrote down the daily dose in every published human study we could verify where people took NMN on its own, with how long it lasted and what changed.

In 30 seconds: We found 20 published human studies of NMN taken on its own. Seventeen gave it every day, at 250 to 2,000 mg a day, for 7 days to 24 weeks. Three tested single doses of 100 to 500 mg. The most common daily amount was 250 mg, used in 9 of the 17 daily studies. The highest, 2,000 mg a day, was a pharmaceutical-grade tablet given for up to 28 days. The longest study ran 24 weeks at 250 mg a day, in 14 older men. Nobody has worked out an ideal dose, and no study lasted longer than 24 weeks. This page reports what studies used. It is not dosing advice, so talk to your doctor before you start.

By BoneScience Journal · Sources checked against PubMed and PubMed Central on November 19, 2026 · Last reviewed November 19, 2026

NMN dose at a glance

Each row counts the daily studies that tested that amount. Some tested more than one dose, so they appear in more than one row.

NMN a day Studies Longest study at this dose
250 mg 9 24 weeks
300 mg 3 60 days
600 mg 2 60 days
900 mg 1 60 days
1,000 mg 2 14 days
1,200 mg 2 6 weeks
1,250 mg 1 4 weeks
2,000 mg 2 28 days

Single doses of 100, 250, 300 and 500 mg were tested in three more studies, covered further down.

Every daily NMN study we found

All of these gave NMN by mouth, on its own, and published results. Fifteen of the 17 compared NMN with a placebo; two had no placebo group, and the table says so. Our NMN evidence guide counts 12 studies: nine of these trials, which used 250 to 1,250 mg a day, plus three reviews that pooled trials. This table adds every other daily study we could verify, from the lowest dose to the highest.

Study Who NMN a day How long What was measured What changed What did not
Yoshino 2021
PMID 33888596
25 women after menopause with prediabetes and overweight or obesity (13 took NMN) 250 mg 10 weeks Muscle insulin sensitivity, NAD+ in blood cells and muscle, body fat, blood tests Muscle insulin sensitivity rose. NAD+ in blood cells rose. Muscle NAD+, body fat, blood pressure, blood sugar and blood fats did not change.
Igarashi 2022
PMID 35927255
42 healthy men aged 65 and older (21 took NMN; 20 men finished 12 weeks) 250 mg 6 or 12 weeks Blood NAD+, walking speed, grip strength, body composition, blood tests Blood NAD+ and related compounds rose. Gains in walking speed and left-hand grip were weak and need confirming in larger studies. Body composition did not change.
Kim 2022
PMID 35215405
108 older adults (54 took NMN, in the morning or the afternoon) 250 mg 12 weeks Sleep quality, fatigue, chair-stand, grip and walking tests Afternoon NMN showed the largest effect on a chair-stand test and on drowsiness. Placebo groups also improved on some measures.
Okabe 2022
PMID 35479740
30 healthy adults aged 20 to 65 (15 took NMN) 250 mg 12 weeks Safety (exams, blood and urine tests), whole-blood NAD+ Whole-blood NAD+ rose. No abnormal exam or lab results. Health benefits were not tested.
Katayoshi 2023
PMID 36797393
36 healthy middle-aged adults 250 mg (125 mg twice a day) 12 weeks NAD+ and related compounds in serum, artery stiffness, blood tests Serum nicotinamide, a product of NAD+ breakdown, rose. Serum NAD+ was too low to measure. Artery stiffness did not differ from placebo.
Akasaka 2023
PMID 36443648
14 men aged 65 and older with diabetes and weak grip or slow walking (average age 81; 7 took NMN) 250 mg 24 weeks Safety, grip strength, walking speed No safety problems over 24 weeks. Grip strength and walking speed were no better than placebo.
Yamane 2023
PMID 37344088
11 healthy volunteers, no placebo group 250 mg (in the morning) 12 weeks Plasma NMN and NAD+, blood tests after lunch Plasma NMN, NAD+ and after-meal insulin rose. The rise in NMN and insulin varied widely between people. No placebo group to compare against.
Yamaguchi 2024
PMID 38191197
11 healthy middle-aged Japanese men, no placebo group 250 mg (two 125 mg capsules before breakfast) 8 weeks Safety, metabolism, sleep, NAD+ in blood cells NAD+ in blood cells rose over the 8 weeks. No placebo group to compare against.
Morifuji 2024
PMID 38789831
60 older adults 250 mg 12 weeks Stepping test (main outcome), walking, sleep, blood NAD+ Blood NAD+ rose. The 4-meter walk was faster and sleep scores were better than placebo at 12 weeks. The main outcome, a stepping test, did not differ from placebo.
Huang 2022
PMID 35821806
66 healthy adults aged 40 to 65 (31 per group analyzed) 300 mg (two 150 mg capsules after breakfast) 60 days Serum NAD+/NADH, 6-minute walk, SF-36 health survey, blood tests Serum NAD+/NADH rose 38% from the start with NMN and 14.3% with placebo by day 60. In the paper's tables, neither the NAD+/NADH change nor walking distance differed significantly from placebo.
Yi 2023
PMID 36482258
80 healthy middle-aged adults (20 per group) 300, 600 or 900 mg 60 days Blood NAD, 6-minute walk, insulin resistance, SF-36 health survey, safety Blood NAD rose in every NMN group, highest at 600 and 900 mg. Walking distance rose more than placebo at all three doses. Insulin resistance (HOMA-IR) did not differ from placebo.
Liao 2021
PMID 34238308
48 recreational runners (12 per group: 10 men, 2 women) 300, 600 or 1,200 mg 6 weeks, with training 5 to 6 times a week Oxygen use and power on an exercise test Some measures of oxygen use and power during the exercise test rose more than placebo at 600 and 1,200 mg. VO2max and peak power did not change from the start in any group.
Christen 2026
PMID 41540253
67 healthy adults aged 18 to 50 in four groups (15 took NMN) 1,000 mg 14 days Blood NAD+, effects on gut microbes Blood NAD+ rose, about as much as with nicotinamide riboside (NR). In the 4 hours after a dose, NMN did not change blood NAD+ compounds; only nicotinamide did.
Pencina 2023a
PMID 35182418
32 adults aged 55 to 80 with overweight or obesity 1,000 mg once or twice a day (1,000 or 2,000 mg), pharmaceutical-grade tablet 14 days Blood NMN, NAD and related compounds, safety Blood NAD rose with dose. Blood NMN rose 1.7 times above baseline on 1,000 mg once a day and 3.7 times on twice a day. Changes did not depend on sex, body mass index or age. Health outcomes were not tested.
Yang 2026
PMID 41705654
11 untrained young men; each took NMN and placebo (crossover) 1,200 mg (300 mg four times a day) 7 days Muscle biopsies before and after a hard leg workout done with blood-flow restriction Some inflammation signals in muscle were lower with NMN. The 171% rise in muscle mitochondria 24 hours after the workout did not happen with NMN.
Fukamizu 2022
PMID 36002548
31 healthy adults aged 20 to 65 (16 took NMN) 1,250 mg Up to 4 weeks Safety only: blood, urine, body composition, vital signs No changes beyond normal variation. Benefits were not tested.
Pencina 2023b
PMID 36740954
30 adults aged 45 and older with overweight or obesity (2 of every 3 took NMN) 2,000 mg (two 500 mg tablets twice a day), pharmaceutical-grade tablet 28 days Safety, blood NAD, body weight and fat, blood pressure, blood fats, insulin sensitivity, strength and fitness Blood NAD and related compounds rose. We report dose, NAD and safety only for this tablet; see the note below the table.

Pencina 2023a and 2023b tested a pharmaceutical-grade NMN tablet. For those two we list dose, blood NAD and safety only; their other results are in the papers. A 2026 review that pooled 15 trials found no clear effect of NMN on body weight, blood sugar, blood fats or systolic blood pressure.

Single-dose studies

These looked at what happens in the minutes or hours after one dose. They tell you little about taking NMN every day.

Study Who NMN dose How long What was measured What changed What did not
Irie 2020
PMID 31685720
10 healthy men, no placebo group Single doses of 100, 250 and 500 mg 5 hours of checks after each dose Symptoms, vital signs, blood tests, NMN breakdown products, eye exam, sleep NMN breakdown products in blood rose with dose. Bilirubin rose and creatinine, chloride and glucose fell, all within normal ranges. No symptoms, and no change in heart rate, blood pressure, oxygen level or temperature. Eye exams and sleep scores did not change.
Wakabayashi 2026
PMID 42304075
14 healthy men, 13 of whom completed both forms (crossover) 250 mg once, swallowed or held under the tongue 60 minutes of blood tests Blood NMN, NAD+ and breakdown products Two breakdown products (2PY and 4PY) rose faster under the tongue. Blood NMN, nicotinamide and NAD+ did not differ between the two ways. Only the under-the-tongue route raised blood NAD+ above its starting level, at 30 minutes.
Zhao 2026
PMID 41651893
60 male physical-education students aged 18 to 28 (15 per group) 300 mg once, 60 minutes before exercise Single dose Body-awareness questionnaires and exercise capacity on a treadmill test No change specific to NMN. NMN alone did not change body-awareness scores. Exercise capacity did not differ among groups.

Does a higher dose do more?

Three daily trials tested more than one dose side by side.

  • Yi 2023, 300 to 900 mg for 60 days. Blood NAD rose in every NMN group and was highest at 600 and 900 mg. Walking distance in a 6-minute test rose more than placebo at all three doses, most at 600 and 900 mg. The authors wrote that the effects they measured reached their highest at 600 mg a day.
  • Liao 2021, 300 to 1,200 mg for 6 weeks. In runners who were also training, some measures of oxygen use rose more than placebo in the 600 and 1,200 mg groups. VO2max and peak power did not change in any group.
  • Pencina 2023a, 1,000 or 2,000 mg for 14 days. Taking the 1,000 mg tablet twice a day instead of once raised blood NMN 3.7 times above baseline instead of 1.7 times, and blood NAD rose with dose.

Two cautions. People on the same dose responded very differently: in a later analysis of the 80-person trial, the rise in blood NAD varied widely within each dose group, and a 12-week study saw the rise in blood NMN vary widely from person to person. And a higher NAD number in the blood is not the same thing as a health benefit. The authors of the later analysis wrote that the ideal dose is still unclear.

Timing and how NMN was taken

  • Morning or afternoon. One 12-week trial in 108 older adults compared 250 mg taken in the morning or the afternoon. The afternoon group showed the largest effects on a chair-stand test and on drowsiness, but placebo groups improved on some measures too. It is one trial, so there is no settled answer.
  • Once or split. Many studies gave NMN once a day. Others split it: 125 mg twice a day, 1,000 mg twice a day, or 300 mg four times a day. None of these studies compared the same daily total taken at once versus split.
  • With or without food. Some studies gave NMN before breakfast and others after breakfast. None compared taking it with and without food.
  • Under the tongue. One study gave 14 men a 250 mg tablet, swallowed on one day and held under the tongue on another; 13 completed both. Over the next hour, blood NMN, nicotinamide and NAD+ did not differ between the two ways, while two breakdown products rose faster under the tongue. It followed people for 60 minutes only.
  • How soon blood NAD rises. Blood NAD+ was higher after 14 days at 1,000 mg a day, and by day 30 at 300 to 900 mg a day.

What these studies cannot tell you

  • Your dose. They show what was tested, in groups of 10 to 108 people. The ideal amount is still unclear.
  • Anything past 24 weeks. 16 of the 17 daily studies lasted 12 weeks or less. The longest ran 24 weeks.
  • Children or pregnancy. None of the studies was designed for children, teenagers, or pregnant or breastfeeding women.
  • Your product. The studies used different NMN products, including a pharmaceutical-grade tablet. A result with one may not carry over to another.
  • Fully independent results. In at least 9 of the 20 studies, a company paid for the work or employed some of the authors. The papers disclose this.

What we left out

  • A study that gave NMN into a vein instead of by mouth.
  • A study done mostly in mice that also gave volunteers aged 45 to 60 NMN at 300 mg a day for 90 days, with no placebo group (PMID 34912838).
  • Studies that mixed NMN with other ingredients, so its own effect cannot be separated.
  • Studies in hospital patients or in people taking NMN for a specific illness.
  • Later re-analyses of trials already in the tables. Each trial is counted once.
  • A 42-day open-label study in Japan whose NMN-only drink was listed at 3,000 mg a day for 9 people. The authors wrote that the amounts still had to be checked against manufacturing records, so we did not count it.

Questions readers ask

How much NMN should I take per day?
Studies can show what was tested, not what you should take. Daily studies used 250 to 2,000 mg a day, and 250 mg was the most common amount, used in 9 of 17. Talk to your doctor about what fits you, especially if you take prescription medicine.
Is 250 mg of NMN a day enough?
At 250 mg a day, several 8- to 12-week studies found that NAD+ or related compounds in the blood went up. Whether that amount leads to a health benefit is not settled: some outcomes improved in some trials and not in others.
Is 1,000 mg of NMN a day too much?
Six daily studies gave 1,000 mg a day or more, for 7 days to 6 weeks. Side effects were mostly mild in the studies that reported them. These were small, short studies, so they cannot show what happens over months.
What is the highest NMN dose tested in people?
2,000 mg a day, in two trials of a pharmaceutical-grade NMN tablet that lasted 14 and 28 days. Adverse events were about as common as on placebo. The most given at one time was 1,250 mg, once a day for up to 4 weeks. Among studies of a single one-time dose, the highest was 500 mg.
What time of day should I take NMN?
One 12-week trial compared 250 mg taken in the morning or the afternoon by older adults. The afternoon group showed the largest effects on a chair-stand test and on drowsiness, but placebo groups improved on some measures too. It is a single trial, so there is no settled answer.
How long does NMN take to raise NAD levels?
In the trials that checked, blood NAD+ was higher after 14 days at 1,000 mg a day and by day 30 at 300 to 900 mg a day. In a one-hour test of a single 250 mg tablet, only the under-the-tongue route raised blood NAD+ above its starting level.
Is sublingual NMN better than swallowing it?
One study compared the two in 13 men who took a 250 mg tablet both ways. Over 60 minutes, blood NMN, nicotinamide and NAD+ did not differ between them, though two breakdown products rose faster under the tongue. We found no study comparing them over weeks of use.
Prime NMN bottle by BoneScience
About BoneScienceBoneScience makes Prime NMN with Uthever® NMN, 250 mg per serving, with every ingredient and its amount listed on the label.*
See Prime NMN

The studies above were not conducted on BoneScience products.

Related: Does NMN Work? What 12 Human Studies Actually Found · Does NMN Have Side Effects? What 20 Human Studies Reported · NMN and NAD+: What 3 Human Trials Actually Found

Sources

  1. Yoshino M, et al. Science. 2021;372(6547):1224-1229. PubMed · doi
  2. Igarashi M, et al. NPJ Aging. 2022;8(1):5. PubMed · doi
  3. Kim M, et al. Nutrients. 2022;14(4):755. PubMed · doi
  4. Okabe K, et al. Front Nutr. 2022;9:868640. PubMed · doi
  5. Katayoshi T, et al. Sci Rep. 2023;13(1):2786. PubMed · doi
  6. Akasaka H, et al. Geriatr Gerontol Int. 2023;23(1):38-43. PubMed · doi
  7. Yamane T, et al. Clin Nutr ESPEN. 2023;56:83-86. PubMed · doi
  8. Yamaguchi S, et al. Endocr J. 2024;71(2):153-169. PubMed · doi
  9. Morifuji M, et al. Geroscience. 2024;46(5):4671-4688. PubMed · doi
  10. Huang H. Front Aging. 2022;3:851698. PubMed · doi
  11. Yi L, et al. Geroscience. 2023;45(1):29-43. PubMed · doi
  12. Liao B, et al. J Int Soc Sports Nutr. 2021;18(1):54. PubMed · doi
  13. Christen S, et al. Nat Metab. 2026;8(1):62-73. PubMed · doi
  14. Pencina KM, et al. J Gerontol A Biol Sci Med Sci. 2023;78(1):90-96. PubMed · doi
  15. Yang DL, et al. J Int Soc Sports Nutr. 2026;23(1):2632284. PubMed · doi
  16. Fukamizu Y, et al. Sci Rep. 2022;12(1):14442. PubMed · doi
  17. Pencina KM, et al. J Clin Endocrinol Metab. 2023;108(8):1968-1980. PubMed · doi
  18. Irie J, et al. Endocr J. 2020;67(2):153-160. PubMed · doi
  19. Wakabayashi J, et al. Sci Rep. 2026;16(1):27464. PubMed · doi
  20. Zhao C, et al. Sci Rep. 2026;16(1):5408. PubMed · doi
  21. Kuerec AH, et al. Mech Ageing Dev. 2024;218:111917. PubMed · doi
  22. Yang W, et al. Nutrients. 2026;18(14):2251. PubMed · doi
  23. Abe T, et al. Nutrients. 2026;18(21):3490. PubMed · doi

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for general education and is not medical advice.


← Older Post Newer Post →

Leave a comment

Please note, comments must be approved before they are published